CervoMed Inc.
CervoMed Inc. (Nasdaq: CRVO) is a clinical-stage biotechnology company developing innovative treatments for age-related brain disorders. The company's lead drug candidate, neflamapimod, is an investigational orally administered small-molecule that selectively inhibits p38α, an enzyme believed to drive… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CervoMed Inc. does
In the company’s own words
CervoMed Inc. (Nasdaq: CRVO) is a clinical-stage biotechnology company developing innovative treatments for age-related brain disorders. The company's lead drug candidate, neflamapimod, is an investigational orally administered small-molecule that selectively inhibits p38α, an enzyme believed to drive neuroinflammation and synaptic dysfunction in neurodegenerative diseases. By targeting neuroinflammation, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
CervoMed's primary focus is advancing neflamapimod for dementia with Lewy bodies, the second most common progressive dementia affecting millions worldwide, for which no approved treatments currently exist in the United States or European Union. The company's differentiated approach targets DLB patients without Alzheimer's disease co-pathology, a population representing approximately fifty percent of all DLB cases. This strategy enables demonstration of clinical effects in shorter trial durations with fewer patients compared to traditional neurodegenerative disease development programs. Beyond DLB, neflamapimod is in clinical development for non-fluent variant primary progressive aphasia, recovery after stroke, and amyotrophic lateral sclerosis.
The company was formed through a merger completed on August 16, 2023, between Diffusion Pharmaceuticals Inc. and EIP Pharma Inc., with EIP surviving as a wholly-owned subsidiary. CervoMed's clinical pipeline includes the RewinD-LB Phase 2b trial, which demonstrated statistically significant improvements on clinical endpoints and biomarkers of neurodegeneration. In November 2025, the company announced alignment with the FDA on key aspects of its planned Phase 3 clinical trial in DLB, which is anticipated to initiate in the second half of 2026. The company received a $21.3 million grant from the National Institute on Aging to support the RewinD-LB Trial. CervoMed is classified as a smaller reporting company and non-accelerated filer. The company's website is www.cervomedpharma.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1053691
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CervoMed Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CervoMed Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CervoMed Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CervoMed Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CervoMed Inc.'s last four quarterly filings that the numbers alone won't show?”